Assessment of Antimicrobial Utilization among Cancer Patients with Febrile Neutropenia at the Lebanese Hospitals

被引:0
|
作者
Cherri, Sarah [1 ]
Malaeb, Diana [1 ,2 ]
Shouman, Lamis [1 ]
Fahs, Iqbal [1 ]
Hallit, Rabih [3 ,4 ,5 ]
Hallit, Souheil [3 ,6 ,7 ]
Malaeb, Bassem [8 ]
Salameh, Pascale [9 ,10 ,11 ,12 ]
机构
[1] Lebanese Int Univ, Sch Pharm, Beirut, Lebanon
[2] Gulf Med Univ, Coll Pharm, Ajman, U Arab Emirates
[3] Holy Spirit Univ Kaslik, Sch Med & Med Sci, Jounieh, Lebanon
[4] Bellevue Med Ctr, Dept Infect Dis, Mansourieh, Lebanon
[5] Univ Hosp Ctr, Notre Dame Secours, Dept Infect Dis, Byblos, Lebanon
[6] Effat Univ, Coll Human, Psychol Dept, Jeddah 21478, Saudi Arabia
[7] Psychiat Hosp Cross, Res Dept, Jal Eddib, Lebanon
[8] Dr Sulaiman Al Habib Med Grp, Dubai, U Arab Emirates
[9] Inst Natl Sante Publ Epidemiol Clin & Toxicol, INSPECT LB, Beirut, Lebanon
[10] Lebanese Amer Univ, Sch Med, Byblos, Lebanon
[11] Univ Nicosia, Sch Med, Dept Primary Care & Populat Hlth, Nicosia, Cyprus
[12] Lebanese Univ, Fac Pharm, Hadat, Lebanon
关键词
Antibiotic; antifungal; antiviral; febrile neutropenia; evaluation; hospital; INFECTIOUS-DISEASES SOCIETY; BLOOD-STREAM INFECTIONS; EMPIRICAL-TREATMENT; FEVER; EPIDEMIOLOGY; THERAPY; RISK; GUIDELINES; MANAGEMENT; CEFEPIME;
D O I
10.2174/1574886317666220620153115
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Febrile neutropenia is a prevalent oncologic complication. Initiating rapid treatment with empirical antimicrobials in febrile neutropenia patients reduces mortality due to infections. Objectives: The study aims to evaluate antimicrobial utilization among FN patients in Lebanon in terms of drug choice, dose, and duration of the treatment. This is a retrospective, multicenter, observational study conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America ( IDSA) guidelines are adopted), between February 2014 and May 2017. Methods: Adult cancer patients aged 18 years and older with febrile neutropenia were included in the study. Using the IDSA guidelines as a reference, patients were assessed whether they received the antimicrobial regimen inconsistent with the IDSA reference or not. Statistical analysis was performed using the Statistical Package for the Social Science software (SPSS version 22.0). The adherence to guidelines for the indication and doses of antibiotics and anti-fungal in patients with febrile neutropenia. Results: A total of 124 patients with a mean age of 54.43 +/- 17.86 years were enrolled in the study. Leukemia (29.7%) was the most prevalent cancer and the most common infection was sepsis (20.2%). Combination antibiotic lactams are the most prescribed antibiotics (86.8%). Only 94 (86.23%) patients were given the antibiotic therapy appropriate for choice, dose, and duration. Empirical antifungal therapy was initiated in 63.7% of the patients and fluconazole was the most used antifungal (36.3%). In contrast to antibiotics, the majority of antifungal choices were not selected according to the recommendations and they were considered inappropriate for doses and the required treatment duration as proposed by (IDSA). Fifty-eight percent of patients received antivirals, even though it is not recommended as empirical treatment. Conclusion: In conclusion, this study reveals a non-consistent antimicrobial utilization practice at the involved sites concerning FN treatment. Inappropriateness was encountered in drug selection, dose, and duration of treatment with antifungals and antivirals.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [21] Febrile neutropenia in cancer patients: Clinical presentations
    Akalin, HE
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 711 - 713
  • [22] Evaluation and management of febrile neutropenia in patients with cancer
    Cossey, Jason
    Cote, Mary Claire B.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (08): : 16 - 20
  • [23] Direct costs of febrile neutropenia in cancer patients
    van Gogh, Evelien
    Specenier, Pol
    Strens, Danielle
    ACTA CLINICA BELGICA, 2017, 72 : 13 - 13
  • [24] Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms
    Rosa R.G.
    Dos Santos R.P.
    Goldani L.Z.
    BMC Research Notes, 7 (1)
  • [25] Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From US Hospitals, 2007-2010
    Dulisse, Brian
    Li, Xiaoyan
    Gayle, Julie A.
    Barron, Richard L.
    Ernst, Frank R.
    Rothman, Kenneth J.
    Legg, Jason C.
    Kaye, James A.
    BLOOD, 2012, 120 (21)
  • [26] Asymmetric dimethylarginine in the assessment of febrile neutropenia in hematological patients
    Lappalainen, Marika
    Hamalainen, Sari
    Juutilainen, Auni
    Koivula, Irma
    Pulkki, Kari
    Jantunen, Esa
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2017, 77 (02): : 130 - 134
  • [27] Risk Assessment of Adult Patients with Febrile Neutropenia and Malignancies
    Alejandria, Marissa M.
    Jamias, Jade
    Ecarma, Raquel
    Zoleta, Loreta
    Mendoza, Myrna
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S106 - S106
  • [28] The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand
    Pimsi, P.
    Santimaleeworagun, W.
    Therasakvichya, S.
    Saengsukkasemsak, N.
    Laocharoenkeat, A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (02) : 242 - 246
  • [29] Knowledge, attitude and practice towards chemotherapy-related neutropenia and febrile neutropenia among breast cancer patients
    Chen, Yilin
    Zhou, Huanhao
    Jiang, Junzhen
    BMJ OPEN, 2024, 14 (10):
  • [30] BODY MASS INDEX FOR SCREENING BACTEREMIA AMONG PEDIATRIC CANCER PATIENTS WITH FEBRILE NEUTROPENIA
    Ojha, R.
    Aviles-Robles, M.
    Johnson, K. M.
    Phillips, B.
    Caniza, M. A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S398 - S398